title: Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer.
abstract: Recently, the National Surgical Adjuvant Study of Colorectal Cancer in Japan, a randomised controlled trial of oral uracil-tegafur (UFT) adjuvant therapy for stage III rectal cancer, showed remarkable survival gains, compared with surgery alone. To evaluate value for money of adjuvant UFT therapy, cost-effective analysis was carried out. Cost-effectiveness analysis of adjuvant UFT therapy was carried out from a payer's perspective, compared with surgery alone. Overall survival and relapse-free survival were estimated by Kaplan-Meier method, up to 5.6 years from randomisation. Costs were estimated from trial data during observation. Quality-adjusted life-years (QALYs) were calculated using utility score from literature. Beyond observation period, they were simulated by the Boag model combined with the competing risk model. For 5.6-year observation, 10-year follow-up and over lifetime, adjuvant UFT therapy gained 0.50, 0.96 and 2.28 QALYs, and reduced costs by $2457, $1771 and $1843 per person compared with surgery alone, respectively (3% discount rate for both effect and costs). Cost-effectiveness acceptability and net monetary benefit analyses showed the robustness of these results. Economic evaluation of adjuvant UFT therapy showed that this therapy is cost saving and can be considered as a cost-effective treatment universally accepted for wide use in Japan.
authors.affiliation: The Institute of Healthcare Technology Assessment, Tokushima 770-0044, Japan. akih@k3.dion.ne.jp
authors.forename: A
authors.initials: A
authors.lastname: Hisashige
authors.forename: S
authors.initials: S
authors.lastname: Yoshida
authors.forename: S
authors.initials: S
authors.lastname: Kodaira
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics*; D017024:Chemotherapy, Adjuvant / Q000191:economics; D003362:Cost-Benefit Analysis; D013505:Digestive System Surgical Procedures; D005260:Female; D006801:Humans; D007564:Japan; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D019057:Quality-Adjusted Life Years; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage / Q000191:economics; D014498:Uracil / Q000008:administration & dosage / Q000191:economics
chemical_list: D005641:Tegafur; D014498:Uracil
references.citation: N Engl J Med. 2004 Oct 21;351(17):1731-40
references.pmid: 15496622
references.citation: Lancet. 2001 Oct 20;358(9290):1291-304
references.pmid: 11684209
references.citation: Ann Oncol. 1997 Jan;8(1):65-70
references.pmid: 9093709
references.citation: Health Econ. 2004 May;13(5):429-36
references.pmid: 15127423
references.citation: Annu Rev Public Health. 1997;18:105-34
references.pmid: 9143714
references.citation: J Clin Oncol. 2005 Sep 1;23(25):6199-206
references.pmid: 16135487
references.citation: Med Decis Making. 2004 Mar-Apr;24(2):131-41
references.pmid: 15090099
references.citation: Br J Cancer. 2007 Feb 12;96(3):439-44
references.pmid: 17245343
references.citation: Pharmacoeconomics. 2007;25(7):537-62
references.pmid: 17610336
references.citation: N Engl J Med. 2004 Jun 3;350(23):2343-51
references.pmid: 15175436
references.citation: Br J Cancer. 2006 Jan 16;94(1):69-73
references.pmid: 16404362
references.citation: Jpn J Clin Oncol. 2006 Apr;36(4):191-2
references.pmid: 16684858
references.citation: J Clin Oncol. 2000 Sep 15;18(18):3302-17
references.pmid: 10986064
references.citation: Eur J Cancer. 2002 May;38(7):953-63
references.pmid: 11978520
references.citation: J Clin Oncol. 2006 May 1;24(13):2059-64
references.pmid: 16648506
references.citation: Eur J Gastroenterol Hepatol. 2004 Jun;16(6):551-61
references.pmid: 15167156
references.citation: J Natl Cancer Inst. 1988 Mar 2;80(1):21-9
references.pmid: 3276900
references.citation: Acta Oncol. 2001;40(2-3):282-308
references.pmid: 11441937
references.citation: Langenbecks Arch Surg. 1998 Dec;383(6):409-15
references.pmid: 9921940
references.citation: Surg Oncol. 2004 Aug-Nov;13(2-3):63-73
references.pmid: 15572088
references.citation: Cancer. 2007 Mar 15;109(6):1082-9
references.pmid: 17265519
references.citation: J Clin Oncol. 2004 Feb 1;22(3):484-92
references.pmid: 14752071
references.citation: Jpn J Clin Oncol. 1999 Feb;29(2):78-86
references.pmid: 10089948
references.citation: Pharmacoeconomics. 2001;19(6):609-21
references.pmid: 11456210
references.citation: N Engl J Med. 2005 Jun 30;352(26):2696-704
references.pmid: 15987918
references.citation: Langenbecks Arch Surg. 2002 Mar;386(8):575-81
references.pmid: 11914933
references.citation: Clin Gastroenterol Hepatol. 2006 Jul;4(7):808-21
references.pmid: 16797250
references.citation: Biometrics. 1997 Jun;53(2):419-34
references.pmid: 9192444
references.citation: Am J Gastroenterol. 1999 Jun;94(6):1650-7
references.pmid: 10364039
references.citation: JAMA. 2000 Aug 23-30;284(8):1008-15
references.pmid: 10944647
references.citation: Expert Rev Pharmacoecon Outcomes Res. 2001 Oct;1(1):25-36
references.pmid: 19807505
references.citation: Ann Surg Oncol. 2006 Aug;13(8):1021-34
references.pmid: 16897272
references.citation: Pharmacoeconomics. 2004;22 Suppl 4:5-10
references.pmid: 15876007
references.citation: Jpn J Clin Oncol. 2006 Apr;36(4):237-44
references.pmid: 16675478
references.citation: BMJ. 2005 Aug 20;331(7514):446-8
references.pmid: 16110075
references.citation: Pharmacoeconomics. 2005;23(7):639-49
references.pmid: 16173156
references.citation: N Engl J Med. 2001 Aug 30;345(9):638-46
references.pmid: 11547717